Study of bioequivalence of magnesium and sodium valproates.
The in vivo bioavailability of magnesium valproate (500 and 1000 mg) enteric-coated tablets has been compared with that of sodium valproate (Depakine) (500 and 1000 mg) enteric-coated tablets. The two preparations were found to be bioequivalent; magnesium valproate appeared to be a drug without bioavailability problems and with reduced inter-subject variability, compared with that of sodium valproate. A reversed-phase HPLC method for the determination of valproates is described.
Balbi
A
A
Istituto di Scienze Farmaceutiche, Università di Genova, Italy.
Sottofattori
E
E
Mazzei
M
M
Sannita
W G
WG
D000284:Administration, Oral; D000328:Adult; D002626:Chemistry, Pharmaceutical; D002851:Chromatography, High Pressure Liquid / Q000379:methods; D006801:Humans; D008274:Magnesium; D008297:Male; D011897:Random Allocation; D012964:Sodium; D013810:Therapeutic Equivalency; D014635:Valproic Acid / Q000097:blood / Q000493:pharmacokinetics*
D014635:Valproic Acid; D012964:Sodium; D008274:Magnesium